|
| 31168593 | Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. | Rheumatology (Oxford) | 2023 |
| 37098795 | Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. | Arthritis Rheumatol | 2023 |
| 37128826 | Validity, Reliability, and Differential Item Functioning of English and French Versions of the 10-Item Connor-Davidson Resilience Scale in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. | Arthritis Care Res (Hoboken) | 2023 |
| 36624431 | Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. | Respir Res | 2023 |
| 36787101 | A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis. | Arthritis Rheumatol | 2023 |
| 36653124 | Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation. | Ann Rheum Dis | 2023 |
| 36743810 | Percutaneous revascularization for the treatment of refractory digital ischemia in systemic sclerosis. | J Scleroderma Relat Disord | 2023 |
| 36708011 | Reduced digestion of circulating genomic DNA in systemic sclerosis patients with the DNASE1L3 R206C variant. | Rheumatology (Oxford) | 2023 |
| 36727567 | Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic Sclerosis. | ACR Open Rheumatol | 2023 |
| 36629780 | STAT6 suppression prevents bleomycin-induced dermal fibrosis. | FASEB J | 2023 |
| 36241361 | Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis. | Ann Rheum Dis | 2023 |
| 35287250 | Blood Neutrophil Count and Neutrophil-to-Lymphocyte Ratio for Prediction of Disease Progression and Mortality in Two Independent Systemic Sclerosis Cohorts. | Arthritis Care Res (Hoboken) | 2023 |
| 34738736 | Predictors of Perceived Functional Status in Early Systemic Sclerosis: A Prospective Longitudinal Study of an Early Disease Cohort. | Arthritis Care Res (Hoboken) | 2023 |
| 34533286 | Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. | Arthritis Care Res (Hoboken) | 2023 |
| 34514739 | Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. | Arthritis Rheumatol | 2022 |
| 35352506 | 47XXY and 47XXX in Scleroderma and Myositis. | ACR Open Rheumatol | 2022 |
| 35754823 | Contribution of HLA and KIR Alleles to Systemic Sclerosis Susceptibility and Immunological and Clinical Disease Subtypes. | Front Genet | 2022 |
| 35753143 | False positive anti-Topoisomerase I (Scl-70) antibody results in clinical practice: A case series from a scleroderma referral center. | Semin Arthritis Rheum | 2022 |
| 35358372 | Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. | Arthritis Rheumatol | 2022 |
| 35904231 | Stem cell transplantation for systemic sclerosis. | Cochrane Database Syst Rev | 2022 |
| 36294335 | The Effect of Body Fat Distribution on Systemic Sclerosis. | J Clin Med | 2022 |
| 35973804 | Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. | Ann Rheum Dis | 2022 |
| 34919939 | Genetic Associations of Non-Major Histocompatibility Complex Susceptibility Loci with Systemic Sclerosis in a Han Chinese Population. | J Invest Dermatol | 2022 |
| 34937693 | Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time. | Ann Rheum Dis | 2022 |
| 35199009 | Total Percutaneous Revascularization of the Hand to Treat Refractory Digital Ischemia in Advanced Systemic Sclerosis. | JACC Case Rep | 2022 |
| 35108379 | Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. | Rheumatology (Oxford) | 2022 |
| 35048554 | The Effect of Anti-Scl-70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis. | ACR Open Rheumatol | 2022 |
| 33004331 | Genomic Risk Score impact on susceptibility to systemic sclerosis. | Ann Rheum Dis | 2021 |
| 34654463 | Multiomic study of skin, peripheral blood, and serum: is serum proteome a reflection of disease process at the end-organ level in systemic sclerosis? | Arthritis Res Ther | 2021 |
| 34105317 | Reply. | Arthritis Rheumatol | 2021 |
| 34096881 | Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. | Ann Rheum Dis | 2021 |
| 33142016 | Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial. | Arthritis Rheumatol | 2021 |
| 33164325 | Reply. | Arthritis Rheumatol | 2021 |
| 33131208 | Large-Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis. | Arthritis Rheumatol | 2021 |
| 33069728 | Exome-Wide Association Analysis Suggests LRP2BP as a Susceptibility Gene for Endothelial Injury in Systemic Sclerosis in the Han Chinese Population. | J Invest Dermatol | 2021 |
| 33412120 | Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. | Lancet Respir Med | 2021 |
| 33350170 | Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. | Arthritis Rheumatol | 2021 |
| 31342624 | Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. | Arthritis Rheumatol | 2020 |
| 34966900 | Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. | Lancet Rheumatol | 2020 |
| 31757866 | Downregulation of CFIm25 amplifies dermal fibrosis through alternative polyadenylation. | J Exp Med | 2020 |
| 31871193 | <i>HLA</i> and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. | Proc Natl Acad Sci U S A | 2020 |
| 32933919 | Machine learning predicts stem cell transplant response in severe scleroderma. | Ann Rheum Dis | 2020 |
| 32906032 | The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis. | Semin Arthritis Rheum | 2020 |
| 32720753 | Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study. | ACR Open Rheumatol | 2020 |
| 32336038 | Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. | Arthritis Rheumatol | 2020 |
| 32329747 | The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. | JMIR Res Protoc | 2020 |
| 32173657 | Analysis of Anti-RNA Polymerase III Antibody-positive Systemic Sclerosis and Altered GPATCH2L and CTNND2 Expression in Scleroderma Renal Crisis. | J Rheumatol | 2020 |
| 30275260 | Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. | J Rheumatol | 2019 |
| 31672989 | GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. | Nat Commun | 2019 |
| 31718536 | SNP eQTL status and eQTL density in the adjacent region of the SNP are associated with its statistical significance in GWA studies. | BMC Genet | 2019 |